Compare GE HealthCare Technologies Inc. Common Stock (GEHC) vs Philip Morris International Inc. (PM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE HealthCare Technologies Inc. Common Stock vs Philip Morris International Inc. — how do they compare? GE HealthCare Technologies Inc. Common Stock trades at $68.66 (market cap $31.07B), while Philip Morris International Inc. trades at $206.58 (market cap $310.62B). The key difference: Philip Morris International Inc. is far larger — about 10× GE HealthCare Technologies Inc. Common Stock's market cap, and Philip Morris International Inc. pays the higher dividend (3.21%). Which is the better fit depends on your goals.
| GEHC | PM | |
|---|---|---|
Market Cap | $31.07B | $310.62B |
Volume | 3,443,020 | 4,145,126 |
Sector | Health | Consumer Staples |
52-Week High | $88.16 | $205.58 |
52-Week Low | $59.48 | $144.33 |
Enterprise Value | $39.53B | $353.73B |
Dividend Yield | 0.23% | 3.21% |
Typical Hold Time | — | 85 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
Philip Morris International (PM) trades at $202.00, up 0.4% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $212.17. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.20, and maintains robust profitability with a net income margin of 25.56%. Recent news highlights growth in smoke-free products like IQOS and ZYN, now over 40% of revenue, and a raised 2026 EPS forecast due to favorable currency impacts.
The stock offers a compelling growth story driven by smoke-free product expansion and dividend reliability, but faces risks from regulatory pressures and high valuation multiples. With 68% of analysts rating it a Buy, upside exists toward the $225 high target, though investors should monitor debt levels and industry shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GE HealthCare Technologies Inc. Common Stock
GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →
